<DOC>
	<DOCNO>NCT01953770</DOCNO>
	<brief_summary>QUESTIONS AND OBJECTIVES OF ALL-MB-2008 STUDY 1 . Whether early PEG-asparaginase induction lead earlier achievement remission , improvement day 8 15 response lead early reconstitution bone marrow immunocompetence , decrease severe infection early mortality rate ? 2 . Whether use PEG-asparaginase induction allow avoid anthracyclines standard risk group patient reduce treatment myelotoxicity ? 3 . Whether administration 9 dose PEG-asparaginase 1,000 U/m2 instead 18 dos E.coli L-asparaginase 5,000 U/m2 standard risk patient improve treatment outcome ? 4 . Whether administration high dose methotrexate ( 2 g/m2 24 hour ) 1-st consolidation intermediate risk patient result decrease central nervous system relapse incidence improvement event-free overall survival ? Whether increase 6-mercaptopurine start dose 50 mg/m2 1-st consolidation phase ( instead 25 mg/m2 ) decrease relapse risk , would accompany enhanced toxicity ? 5 . Is possible completely avoid cranial irradiation intermediate risk patient ? In subgroup intermediate risk patient ? Is enough control neuroleukemia patient introduce additional TIT consolidation phase treatment ? How change possible late effect patient accord third arm randomization ? 6 . Will new risk group stratification improve overall event-free survival ?</brief_summary>
	<brief_title>Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>1 . Age diagnosis 1 18 year . 2 . The start induction therapy within time interval study recruitment phase . 3 . The diagnosis ALL prove morphological , cytochemical , immunological analysis tumor cell bone marrow . 4 . Informed consent parent ( guardian ) patient treat one clinic include multicenter study . 1 . ALL second malignant tumor ; 2 . The disease relapse previously misdiagnosed , therefore , inadequately treat ALL ; 3 . There severe concomitant disease , significantly impede chemotherapy protocol ( multiple malformation , heart disease , metabolic disorder , etc . ) ; 4 . There lack important basic data need exact adherence cytostatic therapy accord specific protocol chemotherapy ( differential diagnosis acute lymphoblastic/myeloid leukemia possible , stratification accord risk group possible ) ; 5 . The patient treat long time cytotoxic drug ; 6 . There deviation treatment cover protocol and/or due side effect treatment and/or complication disease</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute lymphoblastic leukemia , child , adolescent , L-asparaginase , methotrexate</keyword>
</DOC>